spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

PCI Pharma Services

PCI secures third site for Clinical Trials storage, central logistics and distribution center

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.

The San Diego site is one of PCI’s eight global Clinical locations across the US, EU and Asia Pacific regions – supporting Clinical Trials in more than 100 countries around the world.

PCI’s new two-story 38,000 sq ft state of the art facility – located less than a mile from its existing San Diego campus – will serve as PCI’s main storage, logistics and distribution center on the West Coast. Beyond controlled room temperature, the building will be equipped for Cold Chain requirements for 2-8°C, -20°C, and -80°C with expanded ultra-low freezer capabilities, as well as cryogenic liquid nitrogen storage at -196°C.

The site expansion project will be completed and validated during the fourth quarter of 2019.

PCI’s Mark Shepanski, Executive Director of Operations and Site Lead for San Diego, said: “Securing our third site in San Diego allows us to continue to provide industry-leading reliability, flexibility and quality in clinical supply management services.

“We began to investigate our requirements for the additional facility last year, anticipating our customers would eventually need additional storage space for their larger Clinical studies. As our customers experience continued success, we want to make sure we adapt and grow with them.”

This announcement is the latest reflecting PCI’s commitment to the continued development and expansion of its global clinical supply network in anticipation of future customer needs; a strategy which includes ongoing and considerable capital investment in facilities and increased capacity.

To find out more, please visit here.

About PCI
The global healthcare industry trusts PCI for the development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enables us to address global needs throughout the product life cycle — from preclinical development, clinical investigational studies, commercialization and ongoing supply. Our customers view us as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives.

For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

Contact
Tom Gosschalk / Carrie Lowe at BECG
T: +44 (0)20 3697 7647 / +44 (0)1962 893 913
phone +44 (0)1495 713 633
email sales@pciservices.com
web www.pciservices.com
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>


White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement